Mark H. Kirschbaum, M.D.
Dr. Kirschbaum did his medical oncology and hematology fellowship at the University of Washington-Fred Hutchinson Cancer Research Center in Seattle, WA. He then attended at the famed Dept of Bone Marrow Transplantation at Hadassah University Hospital in Jerusalem, served as a research associate in the Yarden Lab at the Weizmann Institute of Science in Rehovot, Israel, and subsequently joined the faculty, as an attending senior physician in the Dept of Hematology and Bone Marrow Transplantation at the Tel Aviv Sourasky Medical Center.
Dr. Kirschbaum moved to the City of Hope National Cancer Center in Duarte, CA, in 2003. In 2005, he became the Director of New Drug Development in the Dept of Hematology & Hematopoietic Cell Transplantation at City of Hope before coming to Nevada Cancer Institute, where he served as Director of Experimental Therapeutics and Acting Chair of Hematology.
At City of Hope, Dr. Kirschbaum focused his efforts on preclinical and clinical studies using molecular and epigenetic based therapies for hematologic malignancies. He served as the hematologic malignancies coordinator for the California Cancer Consortium, part of City of Hope's federally funded grant for Phase I and Phase II clinical trials through the NIH Cancer Therapy Evaluation Program.
Dr. Kirschbaum's accomplishments included developing and running clinical trials using novel molecular and epigenetic therapies for the treatment of leukemia, lymphoma, and myeloma within his institution and in cooperative groups. He was part of the team that developed the initial reduced intensity stem cell transplant regimen, which is now widely used, and has been involved in clinical and preclinical studies of enhanced conditioning regimens for autologous and allogeneic transplantation.
- Myelodysplastic Syndrome
- Director, Hematologic Malignancies
- Professor of Medicine
Dr. Kirschbaum's clinical trial focus is on novel molecular "smart" drugs with the goal of creating more effective and less toxic therapies that would particularly benefit the older patient population.
Dr. Kirschbaum's current lab research focuses on identifying novel therapies for cancer, with a particular focus on novel epigenetic therapies, such as histone deacetylase inhibitors and their effects upon DNA damage response elements and apoptosis, with the goal of developing novel combination therapies for malignancies and stem cell transplant.